Poolbeg Pharma announces successful site activation for POLB 001 TOPICAL clinical trial
Major operational milestone achieved with interim data on track for summer 2026
11 June 2026- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the first site activation for the first-in-patient POLB 001 TOPICAL* clinical trial has occurred. This follows the successful completion of the site initiation visit, with patient recruitment underway and interim data expected in summer 2026.
